Ireland· IE-PA-EU/1/22/1638/001-002
QUVIVIQ 25 mg film-coated tablets
A daridorexant product containing daridorexant hydrochloride, registered in Ireland by Idorsia Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Daridorexant is registered in 15 of 19 countries.
Countries holding a registration under ATC N05CJ03 (daridorexant), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Daridorexant · ATC N05CJ03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of daridorexant costs, country by country.
Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Daridorexant · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- FR France$3.24
The record
At a glance
HPRA (Ireland)- Active substance
- Daridorexant hydrochloride
- Manufacturer
- Idorsia Pharmaceuticals Deutschland GmbH
- Country
- Ireland (IE)
- ATC code
- N05CJ03
- ATC class
- Daridorexant
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1638/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Daridorexant in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH, Lörrach
- SwitzerlandQUVIVIQ 25 mg , FilmtablettenIdorsia Pharmaceuticals Ltd
- FinlandQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH
- FranceQUVIVIQ 25 mg, comprimé pelliculéIDORSIA PHARMACEUTICALS DEUTSCHLAND (ALLEMAGNE)
- IcelandQuviviqIdorsia Pharmaceuticals Deutschland GmbH
- NetherlandsQuviviq 25 mg, filmomhulde tabletIdorsia Pharmaceuticals Deutschland GmbH
- PolandQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH
- SwedenQUVIVIQ 25 mg Filmdragerad tablettIdorsia Pharmaceuticals Deutschland GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Quviviq
- Liechtenstein · Quviviq
- Norway · Quviviq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/93f4a06c-5093-40f2-9831-7047a3533afa GET /v1/drugs/93f4a06c-5093-40f2-9831-7047a3533afa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"N05CJ03"
],
"strength": null,
"pa_number": "EU/1/22/1638/001-002",
"substances": [
"Daridorexant hydrochloride"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "29/04/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about daridorexant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.